Active ingredients

The drug ABBLE contains a combination of these active pharmaceutical ingredients (APIs):


Bromhexine is an expectorant used in the treatment of respiratory disorders associated with viscid or excessive mucus. Bromhexine is a synthetic derivative of the herbal active ingredient vasicine. It has been shown to increase the proportion of serous bronchial secretion, making it more easily expectorated. It is indicated as “secretolytic therapy in bronchopulmonary diseases associated with abnormal mucus secretion and impaired mucus transport”.

Read about Bromhexine

Noscapine is a benzylisoquinoline alkaloid from plants of the poppy family, without painkilling properties. Noscapine is often used as an antitussive medication. Noscapine can increase the effects of centrally sedating substances such as alcohol and hypnotics. Noscapine, and its synthetic derivatives called noscapinoids, are known to interact with microtubules and inhibit cancer cell proliferation. Mechanisms for its antitussive action are unknown, although animal studies have suggested central nervous system as a site of action. Furthermore, noscapine causes apoptosis in many cell types and has potent antitumor activity against solid murine lymphoid tumors (even when the drug was administered orally) and against human breast and bladder tumors implanted in nude mice. Antifibrotic effect of noscapine based on novel mechanism, which it shows through EP2 prostaglandin E2 receptor-mediated activation of protein kinase A.

Read about Noscapine

Phenylephrine is a sympathomimetic agent with mainly direct effects on adrenergic receptors. It has predominantly alpha adrenergic activity and is without stimulating effects on the central nervous system. The sympathomimetic effect of phenylephrine produces vasoconstriction which in turn relieves nasal congestion.

Read about Phenylephrine

Authorization and marketing

This brand name is authorized in the following countries: Hong Kong

This drug has been assigned below unique identifiers within the countries it is being marketed:

Identification scheme
Department of Health Drug Office
Identifier(s): 62937